Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma ( RRMM) Patients

被引：1
|
作者：
不详
机构：
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-151161
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1616
引用
收藏
页数：4
相关论文
共 50 条
  • [41] a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Berenson, James
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Regina, Swift A.
    James, Wang
    Benjamin, Eades
    Spektor, Tanya M.
    Vescio, Robert
    BLOOD, 2015, 126 (23)
  • [42] Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients
    Nooka, Ajay K.
    Joseph, Nisha S.
    Kaufman, Jonathan L.
    Heffner, Leonard T.
    Gupta, Vikas A.
    Gleason, Charise
    Boise, Lawrence H.
    Lonial, Sagar
    CANCER, 2019, 125 (17) : 2991 - 3000
  • [43] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew J.
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Bianchi, Giada
    O'Donnell, Elizabeth
    Branagan, Andrew R.
    Harrington, Cynthia C.
    Agyemang, Emerentia A.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette A.
    Bernstein, Zachary S.
    Lyons, Rebecca T.
    Riadi, Manal
    Rowell, Sean M.
    Mcvey, Cailin
    Goguen, Amy C.
    Horick, Nora K.
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
    Fazio, Francesca
    Franceschini, Luca
    Tomarchio, Valeria
    Rago, Angela
    Garzia, Maria Grazia
    Cupelli, Luca
    Bongarzoni, Velia
    Andriani, Alessandro
    Gumenyuk, Svitlana
    Tafuri, Agostino
    Siniscalchi, Agostina
    Piciocchi, Alfonso
    De Fabritiis, Paolo
    De Rosa, Luca
    di Toritto, Tommaso Caravita
    Annibali, Ombretta
    Cantonetti, Maria
    Petrucci, Maria Teresa
    EJHAEM, 2022, 3 (01): : 121 - 128
  • [45] Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone
    Alkharabsheh, Omar
    Bellman, Polina
    Mahmoudjafari, Zahra
    Cui, Wei
    Atrash, Shebli
    Paul, Barry
    Hashmi, Hamza
    Shune, Leyla
    Ahmed, Nausheen
    Abdallah, Al-Ola
    JOURNAL OF HEMATOLOGY, 2023, 12 (01) : 1 - 6
  • [46] Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
    Matsue, Kosei
    Iwasaki, Hiromi
    Chou, Takaaki
    Tobinai, Kensei
    Sunami, Kazutaka
    Ogawa, Yoshiaki
    Kurihara, Mari
    Midorikawa, Shuichi
    Zaki, Mohamed
    Doerr, Thomas
    Iida, Shinsuke
    CANCER SCIENCE, 2015, 106 (11): : 1561 - 1567
  • [47] DARATUMUMAB COMBINED WITH DEXAMETHASONE AND LENALIDOMIDE OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS: REPORT FROM THE MULTIPLE MYELOMA GIMEMA LAZIO GROUP
    Fazio, F.
    Franceschini, L.
    Tomarchio, V.
    Rago, A.
    Garzia, M. G.
    Cupelli, L.
    Bongarzoni, V.
    Rosati, S.
    Gumenyku, S.
    Antolino, G.
    Siniscalchi, A.
    Proietti, G.
    Piciocchi, A.
    De Fabritiis, P.
    De Rosa, L.
    Caravita, T.
    Annibali, O.
    Cantonetti, M.
    Petrucci, M. T.
    HAEMATOLOGICA, 2021, 106 (10) : 92 - 92
  • [48] Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
    Pierceall, William E.
    Bahlis, Nizar
    Siegel, David S.
    Schiller, Gary J.
    Samaras, Christy J.
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddhartha
    Matous, Jeffrey V.
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Srinivas, Shanti
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald P.
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Chung, Weiyuan
    Serbina, Natalya
    Zafar, Faiza
    Agarwal, Amit
    Thakurta, Anjan
    BLOOD, 2018, 132
  • [49] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/ Refractory Multiple Myeloma
    Kumar, Anupama
    Rosenberg, Aaron S.
    Padilla, Michelle
    Shah, Nina
    Sirianni, Lindsey
    Liu, Lin
    Cheng, Yuwei
    Pittman, Emily
    Tzachanis, Dimitrios
    Larson, Sarah
    Mulroney, Carolyn
    Ball, Edward D.
    Costello, Caitlin
    BLOOD, 2022, 140 : 4436 - 4437
  • [50] Pomalidomide, Cyclophosphamide and Dexamethasone (PCD) is an effective salvage regimen for multiple myeloma (MM) patients relapsed and/or refractory to Daratumumab (dara)
    Brioli, A.
    Ernst, T.
    Hilgendorf, I.
    Heidel, F.
    Hunstig, F.
    Stauch, T.
    Hochhaus, A.
    von Lilienfeld-Toal, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 278 - 278
12345